Table 3.

Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 25 mg/dL and propensity score-matched patients on placebo

	All (N = 8610)	Alirocumab (N = 4305)	Placebo (N = 4305)
LDL-C, mmol/L	2.1 ± 0.6	2.1 ± 0.6	2.16 ± 0
Non-HDL-C, mmol/L	2.9 ± 0.7	2.9 ± 0.7	2.9 ± 0.7
Total cholesterol, mmol/L	4.0 ± 0.8	4.0 ± 0.8	4.0 ± 0.8
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3
Fasting triglycerides, mmol/L	1.8 ± 1.0	1.8 ± 1.0	1.8 ± 1.1
Lipoprotein(a), mg/dL	28.6 ± 33.1	28.7 ± 33.3	28.7 ± 33.2
Apolipoprotein B, mg/dL	77.6 ± 17.3	78.1 ± 17.5	77.9 ± 17.4
Apolipoprotein A1, mg/dL	131.6 ± 23.0	131.2 ± 22.5	131.4 ± 22.7
Apolipoprotein B/Apolipoprotein A1 ratioa	0.61 ± 0.2	0.61 ± 0.2	0.61 ± 0.2
Total cholesterol/HDL-C ratioa	3.8 ± 1.0	3.8 ± 1.0	3.8 ± 1.0

Data are presented as mean ± SD

HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, Q Quartile, SD Standard deviation

^a Ratios were only calculated if the 2 samples were collected at the same visit